Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl) received FDA approval for treating metastatic cutaneous squamous cell carcinoma (cSCC). This is the first PD-L1 blocking antibody approved for this indication. Unloxcyt is administered intravenously at 1200 mg every three weeks. The approval comes after a previous setback related to manufacturing, not the drug’s efficacy or safety. CKPT stock saw a premarket surge following the news.